Patents Assigned to PHARMATROPHIX, INC.
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 11225467
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 18, 2022
    Assignee: PHARMATROPHIX, INC.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 10532988
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: January 14, 2020
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 10273219
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 30, 2019
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 9884833
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms. In one embodiment, the crystalline compound is (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: February 6, 2018
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Non-peptide BDNF neurotrophin mimetics
    Patent number: 9828330
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 28, 2017
    Assignee: PharmatrophiX, Inc.
    Inventor: Frank M. Longo
  • Deuterated compounds useful for treating neurodegenerative diseases
    Patent number: 9464066
    Abstract: The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: October 11, 2016
    Assignee: Pharmatrophix, Inc.
    Inventor: Damodara Gopal
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 9271986
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 1, 2016
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS
    Publication number: 20160046559
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Applicant: Pharmatrophix, Inc.
    Inventor: Frank M. Longo
  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20130005731
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Application
    Filed: November 12, 2010
    Publication date: January 3, 2013
    Applicant: Pharmatrophix, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20120322799
    Abstract: The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds.
    Type: Application
    Filed: November 30, 2010
    Publication date: December 20, 2012
    Applicant: PHARMATROPHIX, INC.
    Inventor: Gopal Damodara